As an individual progresses from no-NASH to borderline NASH to definite NASH, CYP2C19 transcript abundance decreases to 61% that of the prior grade; reducing CYP2C19 mRNA expression levels by 63% in individuals with NASH compared to those without NASH. Here, CYP2C19 is linked to metabolic dysfunction-associated steatohepatitis.